Fate Therapeutics (FATE) Amortization of Deferred Charges (2012 - 2023)

Fate Therapeutics has reported Amortization of Deferred Charges for 12 years, with the latest figure at $7.2 million in Q1 2023.

• For the quarter ending Q1 2023, Amortization of Deferred Charges rose 557.77% year-over-year to $7.2 million; the trailing twelve-month figure through Dec 2023 stood at $7.2 million (up 168.91% YoY), and the FY2023 full-year result was $7.2 million, up 168.91% from the prior year.
• Amortization of Deferred Charges for Q1 2023 stood at $7.2 million, up from $1.1 million in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $7.2 million in Q1 2023, with the low at -$331000.0 in Q2 2022.
• Historically, Amortization of Deferred Charges has averaged $1.0 million across 5 years, with a median of $623000.0 in 2021.
• Annual changes were most pronounced in 2019 — Amortization of Deferred Charges slumped 347.37% — and 2020, when it soared 1604.07%.
• Fate Therapeutics' Amortization of Deferred Charges stood at -$123000.0 in 2019, then soared by 1604.07% to $1.8 million in 2020, then slumped by 30.43% to $1.3 million in 2021, then fell by 12.2% to $1.1 million in 2022, then surged by 536.81% to $7.2 million in 2023.
• The last three Amortization of Deferred Charges figures came in at $7.2 million (Q1 2023), $1.1 million (Q4 2022), and $783000.0 (Q3 2022), per Business Quant data.